| Trial ID: | L4785 |
| Source ID: | NCT05199090
|
| Associated Drug: |
Mbl949
|
| Title: |
Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT05199090/results
|
| Conditions: |
Obesity
|
| Interventions: |
DRUG: MBL949|DRUG: Placebo
|
| Outcome Measures: |
Primary: Frequency and Severity of Adverse Events, Number of participants with adverse events reported after the first dose of study medication or events present prior to treatment but increase in severity, Baseline to Day 169|Change-from-baseline in Weight, Baseline weight is defined as the last weight measurement before dosing in kilograms, Week 16 |
|
| Sponsor/Collaborators: |
Sponsor: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
126
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-02-10
|
| Completion Date: |
2023-05-11
|
| Results First Posted: |
2024-05-31
|
| Last Update Posted: |
2024-10-09
|
| Locations: |
Novartis Investigative Site, Miami, Florida, 33135, United States|Novartis Investigative Site, Morehead City, North Carolina, 28557, United States|Novartis Investigative Site, Knoxville, Tennessee, 37920, United States|Novartis Investigative Site, Dallas, Texas, 75230, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05199090
|
